Therefore, we used the DEN-induced cirrhotic rat model with HCC to test safety and anti-tumor efficacy of the combination of sorafenib with AKT-inhibitor ARQ 092 (Supplementary Figure 1). The gene discussed is AKT1; the disease is hepatocellular carcinoma.